

## [New Drug Approvals](#)

### Generic Name (Trade Name—Company)

April 18, 2018

### **Fostamatinib disodium hexahydrate**

***(Tavalisse—Rigel Pharmaceuticals)***

**New drug targets chronic immune thrombocytopenia in adults**

### Uses/Notes

Rigel Pharmaceuticals [announced](#) FDA approval of fostamatinib disodium hexahydrate to treat thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

The agent is an oral spleen tyrosine kinase (SYK) inhibitor that targets the underlying autoimmune cause of the disease by impeding platelet destruction, providing an important new treatment option for adult patients with chronic ITP.

FDA approval was supported by data from the FIT clinical program, which included two randomized, placebo-controlled Phase III trials and an open-label extension, as well as an initial proof of concept study. The studies included 163 patients with ITP and was supported by a safety database of more than 4,600 participants across other indications in which fostamatinib has been evaluated.

Rigel plans to launch the new drug in the United States in late May 2018.

### Source URL:

<http://blog.pharmacist.com/new-drug-approvals/new-drug-targets-chronic-immune-thrombocytopenia-adults>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.